M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study
暂无分享,去创建一个
A. Manning | J. Duffner | S. Arroyo | L. Ling | J. Streisand | Nicholas A. Cilfone | L. Markowitz | D. Nix | T. Bosje | J. Hillson | R. Tiessen | Mattheus Paulus (Thijs) van Iersel